Table 6.

Summary of AEs

	Cetuximab ± lenalidomide (N = 40)
	All	Grades 3–4
Total	40 (100%)	26 (65%)
Fatigue	33 (82%)	2 (5%)
Rash	32 (80%)	0 (0%)
Anemia	27 (67%)	3 (8%)
Constipation	18 (45%)	0 (0%)
Anorexia	15 (32%)	1 (3%)
Nausea	11 (28%)	0 (0%)
Mucositis	10 (25%)	0 (0%)
Hypoalbuminemia	10 (25%)	0 (0%)
Leukopenia	10 (25%)	5 (13%)
Lymphopenia	9 (23%)	6 (15%)
Neutropenia	8 (20%)	5 (13%)
Thrombocytopenia	8 (20%)	4 (10%)
Vomiting	7 (20%)	0 (0%)
Hyponatremia	8 (20%)	3 (8%)
Diarrhea	8 (20%)	1 (3%)
Xerostomia	6 (15%)	0 (0%)
Hypomagnesemia	3 (8%)	0 (0%)
Infusion reaction	2 (5%)	1 (3%)
Thromboembolic events	1 (3%)	0 (0%)